Key Takeaways

• ARTL shares skyrocketed 618% following the company’s announcement about developing ART27.13 as a complementary treatment for GLP-1 obesity medications.
• Shares plummeted over 23% Monday when Artelo disclosed a $31.4 million fundraising initiative involving share and warrant issuance.
• The company plans to issue roughly 3.18 million shares priced at $3.45 each, generating approximately $11 million in gross revenue.
• Warrant agreements for up to 6.37 million additional shares could yield another $20.4 million if fully exercised by investors.
• The financing arrangement was structured at-the-market under Nasdaq compliance guidelines and was scheduled to finalize on March 30.

Shares of Artelo Biosciences experienced a significant downturn exceeding 23% during early trading Monday following the biotechnology firm’s announcement of a financing plan targeting up to $31.4 million through combined share and warrant issuance.

Artelo Biosciences, Inc., ARTL

This sharp decline occurred after an impressive 230.41% rally the preceding Friday, which followed by two days the company’s revelation that it was investigating ART27.13, its experimental compound, as a complementary therapeutic option for GLP-1-based obesity medications.

The strategic decision to pursue capital raising immediately following such substantial share price appreciation seems to have triggered investor apprehension regarding potential ownership dilution.

Artelo revealed it executed binding agreements for the sale of roughly 3.18 million common shares at a combined offering price of $3.45 per unit. This transaction is projected to yield gross revenues of approximately $11 million prior to deducting placement fees and related costs.

Additionally, the biotechnology company intends to issue warrants providing purchasers with rights to acquire up to 6.37 million supplementary shares. Should these warrants be fully exercised through cash payment, Artelo could secure an additional $20.4 million in funding.

The company explicitly cautioned investors that warrant exercise remains uncertain. “No assurance can be given that any of the warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the warrants,” Artelo stated in its official announcement.

H.C. Wainwright & Co. serves as the sole placement agent facilitating this financing transaction.

The private offering is being executed pursuant to Section 4(a)(2) of the Securities Act alongside Regulation D requirements. The offered securities remain unregistered under federal and state securities regulations. Artelo has committed to submitting a resale registration statement encompassing the newly issued securities.

Capital generated from this financing will be allocated toward operational expenses, settlement of specific bridge financing obligations, and broader corporate initiatives.

ART27.13’s Role in the GLP-1 Treatment Landscape

The initial dramatic price increase stemmed from Artelo’s Wednesday disclosure regarding its exploration of ART27.13 — an investigational therapeutic targeting the endocannabinoid system — as a possible adjunct therapy to GLP-1 medications.

GLP-1 therapeutics, which regulate glucose metabolism and appetite control, represent the cornerstone of the rapidly expanding obesity pharmaceutical market. This sector is currently led by Eli Lilly (LLY) and Novo Nordisk (NVO).

According to Artelo, previous clinical observations in oncology patients indicated that ART27.13 might help maintain lean muscle tissue in individuals receiving GLP-1 treatments. The company has subsequently submitted a provisional patent application addressing this therapeutic indication.

“With new non-clinical research commencing and the recent filing of a patent application covering the use of CB2 agonists with GLP-1 drugs, we are aiming to build a scientific and strategic foundation with ART27.13 in an area of potentially significant commercial relevance,” stated Andrew Yates, Artelo’s chief scientific officer.

TLDR:

• February 2026 funding rates landed in the bottom 3–15% of all historical monthly readings across major tokens.
• Every bottom-15% funding rate streak on record has recovered, with a median timeline of two to five weeks.
• SOL on Hyperliquid posted -18.33% annualized in February, the lowest reading ever recorded across all tracked pairs.
• Boros allows traders to long ETH funding rate markets and lock in fixed rates ahead of an expected mean reversion.

Funding rates across major crypto perpetual markets are raising a critical question: has the market finally bottomed?

After Bitcoin shed over 50% from its October 2025 all-time highs, perpetual funding rates collapsed to historic lows in February 2026.

Most major tokens recorded readings in the bottom 5% of all-time monthly data. Now, with crypto prices rallying despite US-Iran war escalations, traders are watching funding rates closely for early reversal signals.

February 2026 Funding Rates Dropped to Levels Never Seen Before

Funding rates in February 2026 were not just low — they were structurally outside the normal range of market history.

BTC on Binance recorded an annualized rate of -0.68%, placing it in the bottom 4.5% of all 66 months on record. That reading alone sat 12 percentage points below BTC’s historical mean of 11.8%.

ETH told an even sharper story. Binance recorded ETH at -4.03% annualized, landing in the bottom 3% of all historical monthly readings.

Hyperliquid and Lighter posted similarly depressed figures, with ETH sitting in the bottom 15% and bottom 20% respectively across those platforms.

XRP and SOL absorbed the worst damage of the month. XRP on Hyperliquid posted -12.77%, the single worst month in that market’s entire recorded history.

SOL on Hyperliquid came in at -18.33%, the lowest absolute reading among all tracked pairs across every platform.

The deviation from historical medians reinforces just how extreme the period was. SOL on Hyperliquid deviated 29.2 percentage points from its median.

BTC on Binance, the least extreme major, still deviated 7.0 percentage points. For most tokens, February was not simply a bad month — it was an anomaly by every measurable standard.

Historical Patterns Suggest These Lows Have Always Preceded a Recovery

The most telling data point in this analysis is also the simplest: every bottom-15% funding rate streak in the historical record has recovered.

That pattern holds across multiple assets, exchanges, and market cycles, including the FTX collapse of November 2022.

The median recovery time back to the bottom 55% of funding rates runs roughly two to five weeks after the streak ends.

BTC provides the clearest evidence. Its longest Binance bottom-15% streak lasted 11 weeks, beginning in March 2025.

Most other BTC streaks recovered within one to five weeks. An extended eight-week streak on Hyperliquid in mid-2023 resolved fully within five weeks of ending.

ETH’s most severe historical episode in late August 2022 averaged -18.6% over five weeks. That took 12 weeks to recover to the bottom 55%, the longest recovery on record for ETH.

More recent episodes, however, including early 2025 streaks, resolved in one to five weeks, suggesting the recovery window is compressing as the market matures.

SOL’s November 2022 streak, driven by the FTX collapse, averaged an extraordinary -468.9% annualized. Despite that severity, Binance SOL recovered to the bottom 20% within seven weeks.

Each of these cases points toward the same conclusion: deeply negative funding rates have historically acted as a contrarian signal for a coming recovery, not a permanent new baseline.

Funding Rate Markets on Boros Allow Traders to Position for the Rebound

If funding rates are indeed at a cyclical bottom, the question becomes how traders can express that view efficiently.

Boros, a funding rate derivatives platform, offers two structured approaches for traders looking to capitalize on a mean reversion in funding rates.

The first strategy targets traders who believe ETH prices will recover over the next three months. By longing ETH on any of the three platforms with June maturities — OKX, Binance, or Hyperliquid — and simultaneously longing the ETH funding rate market on Boros with the same notional amount, traders lock in a fixed funding rate. This protects against funding spikes while maintaining full upside exposure to ETH price recovery.

The second strategy is for traders focused purely on funding rate normalization, regardless of price direction. Longing ETH funding rate markets on Boros directly captures any upward move in implied or underlying APR.

The recommended approach is selecting the maturity with the lowest current implied APR to maximize the distance of a potential recovery move.

Implied APR across June ETH maturities currently sits between 2% and 5% annualized, reflecting cautious market expectations for a gradual recovery.

If underlying APR breaks its downtrend and flips positive, traders long on Boros benefit both from rising implied APR and from positive settlement payouts once underlying APR exceeds their entry point.

The Data Points to an Asymmetric Opportunity, But Margin Management Is Critical

Taken together, the February 2026 funding rate data builds a case for an asymmetric setup. Rates have reached historic lows across virtually every major token and exchange.

Historical recovery patterns are consistent. And crypto prices have already begun recovering despite ongoing geopolitical pressure, a divergence that traders are noting carefully.

Extended periods of negative funding have historically reflected consolidating or ranging markets. As Boros observed, those periods of extended low funding have always eventually ended. The question is not whether rates recover, but when — and whether traders are positioned to benefit when they do.

For those looking to long mean reversion, timing the exact bottom is not necessary. The historical data suggests the recovery window after a streak breaks is two to five weeks, giving traders a defined timeframe to manage positions. The risk is sustaining negative funding payouts during the remaining period of the streak before it turns.

Adequate margin is therefore the most important operational variable for this trade. A trader who enters too early with insufficient runway may be forced out before the recovery materializes.

The setup, however, remains compelling: deeply negative historical funding rates, a consistent track record of recovery, and structured tools through Boros that allow both fixed-rate locking and directional funding rate speculation.

TLDR:

• • Gnosis is a founding contributor to the Ethereum Economic Zone alongside Jordi Baylina and the Ethereum Foundation.
    
  • EEZ rollups allow smart contracts to call Ethereum mainnet contracts atomically within a single transaction.
    
  • Protocols on EEZ rollups access Ethereum’s native liquidity directly without wrapping, bridging, or extra delays.
  • Gnosis plans to define the role of GNO token and its validator set in any future EEZ implementation with its DAO.

Ethereum Economic Zone is the framework Gnosis is co-building to address Layer 2 fragmentation on Ethereum. Gnosis, active as a Layer 1 blockchain for seven years, is a founding contributor to this initiative.

Jordi Baylina, founder of ZisK and creator of Circom, also joins as a founding contributor. The Ethereum Foundation is also co-funding the entire development effort.

The framework centers on synchronous composability, enabling rollups to interact with Ethereum mainnet without bridges.

A Framework Built Around Composability

Ethereum scaling delivered on its core promise in recent years. Transactions became cheaper and network throughput increased steadily. However, the process fractured the ecosystem into disconnected chains rather than one unified economy.

Each rollup operates with its own liquidity, bridges, and tooling. Builders must redeploy the same products across multiple chains to reach all users. Users also face expensive bridging costs and assets scattered across chains they barely track.

Gnosis noted on X that Ethereum had scaled into fragmented islands rather than a unified economy. The Ethereum Economic Zone is designed to resolve that at the infrastructure layer. The framework allows rollup smart contracts to call Ethereum mainnet contracts within one transaction.

Calls between different rollups within the same execution are also supported. This is what developers call synchronous composability. It removes the need for bridges, wrapping, or waiting on finality.

Protocols on EEZ rollups access Ethereum’s existing liquidity directly without bridging or wrapping. A protocol can use a Uniswap mainnet pool atomically, with the same L1 guarantees. These rollups also inherit Ethereum’s full validator security with no new trust assumptions added.

What the Ethereum Economic Zone Means for Gnosis Chain

Gnosis acknowledged that its neutral blockspace thesis did not develop as expected. Blockspace became largely commoditized across the industry over time. Running a standalone Layer 1 requires constant rebuilding of DeFi infrastructure and liquidity bootstrapping.

Synchronous interoperability changes the competitive dynamic for chains like Gnosis. Projects inside a composable Ethereum domain no longer need to replicate an entire ecosystem. They can rely on shared liquidity and canonical infrastructure instead.

That shift frees up capital and engineering bandwidth for differentiation. Gnosis plans to invest more in user experiences and products like Gnosis Pay and the Gnosis App. Real-world financial integrations also become more practical under a unified model.

The Ethereum Economic Zone also connects to Gnosis’s mission of giving every person financial access. A stablecoin can now compose with a lending protocol on another chain without a bridge. A consumer app can also access the best rates across the ecosystem without workarounds.

Gnosis noted that the GNO token and validator set may have a role in a future EEZ implementation. Those details will be worked out with the Gnosis DAO community over the coming months. Technical architecture, developer tooling, and integration guides are also planned for release soon.

The Ethereum Foundation is stepping up its efforts to put treasury assets to work, with data from Arkham showing it staked more than 20,000 ETH on Monday, expanding its validator footprint even as yields hover below 3% and ether trades near $2,045.

Arkham data shows the transfers were split into uniform chunks of roughly 2,047 ETH.

The deposits extend a strategy first outlined in February, when the foundation said it would stake 70,000 ETH to generate yield for operations. That initial roll-out began with a 2,016 ETH deposit and positioned staking rewards as a funding source for research, ecosystem development and grants, turning long-held reserves into a steady income stream.

Based on the CoinDesk Composite Ether Staking Rate (CESR), the foundation will get a 2.7% yield from its staked ETH. This is down from 3.4% earlier in the year.

Onchain data shows that the Ethereum Foundation has another 147,400 ETH ($303 million) in its treasury.

The Ethereum Foundation has accelerated its treasury staking push, deploying $46.2 million in Ether in its largest move to date after the recent BitMine sale.

On Monday, the foundation’s treasury multisignature wallet made 11 deposits into the Ethereum Beacon Deposit Contract, each of roughly 2,047 Ether (ETH), totaling 22,517 tokens worth roughly $46.2 million, according to data from Arkham Intelligence.

The Ethereum Foundation started staking ETH in February, depositing 2,016 ETH and outlining plans to stake up to 70,000 ETH, with rewards reinvested into research, ecosystem development and grants.

The foundation also deposited a smaller 31 ETH tranche earlier this month, bringing the total staked holdings to roughly 24,564 ETH as it shifts to staking to generate yield, rather than relying on periodic ETH sales, which have historically drawn criticism.

Related: Ethereum builders propose ‘economic zone’ to tackle L2 fragmentation

EF sells 5,000 ETH to BitMine in OTC deal

The new staking move comes after the EF completed an over-the-counter (OTC) sale of 5,000 Ether to BitMine Immersion Technologies, valued at about $10.2 million. The foundation said proceeds would support core operations, including protocol research, ecosystem growth and community grants.

The transaction marked the foundation’s second direct OTC sale to a corporate buyer, following a 10,000 ETH sale to SharpLink Gaming in July 2025.

The EF currently holds about $361 million in onchain assets, with the vast majority, roughly $360.8 million, held in Ether on the Ethereum network, alongside small balances across networks like Arbitrum, Optimism and Bitcoin, according to Arkham.

Related: Ethereum risks losing No. 2 spot as stablecoins gain ground

Ether price risks further decline

Ether fell below the $2,000 level over the weekend, raising the risk of a deeper correction. Analysts, including Onur, CryptoWZRD and Ted Pillows, pointed to repeated failures at $2,200 and weakening momentum, with some warning ETH could fall toward the $1,750–$1,850 range.

Demand for Ether has also turned negative, hitting its lowest level in 16 months, according to Capriole Investments.

Magazine: Ethereum’s Fusaka fork explained for dummies — What the hell is PeerDAS?